Medicare Enrolled
Dr. Zhaoyang Pan, M.D.
Dermatology · Los Angeles, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Pan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pan
Dr. Zhaoyang Pan is a dermatology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Pan performed 4,301 Medicare services across 1,560 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pan received a total of $43,498 from 66 pharmaceutical and/or device companies across 1602 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in dermatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 12% volume in CA
$43,498 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,301
Medicare services
Top 12% in CA for dermatology
1,560
Unique beneficiaries
$75
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~226 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,671 | $74 | $120 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
349 | $106 | $170 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
255 | $140 | $150 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
186 | $33 | $45 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
175 | $63 | $130 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
144 | $48 | $90 |
| Venipuncture for blood draw Insertion of a needle into a vein to collect blood samples. This procedure is performed on patients aged 3 years or older. |
110 | $15 | $25 |
| Quadrivalent influenza vaccine, cell culture-derived A flu shot that protects against four strains of the influenza virus. It is produced using cell culture technology rather than traditional egg-based methods. |
97 | $32 | $50 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
89 | $76 | $90 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
75 | $12 | $40 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
40 | $89 | $170 |
| Denosumab injection (Prolia/Xgeva) | 34 | $0 | $0 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
25 | $241 | $350 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
22 | $12 | $45 |
| Initial preventive physical examination, new Medicare beneficiary A comprehensive preventive health visit for new Medicare beneficiaries during their first 12 months of enrollment. The service is conducted as a face-to-face visit and is limited to preventive care. |
16 | $179 | $200 |
| Initial nursing facility care, moderate complexity Initial care provided to a patient in a nursing facility with moderate medical decision making, taking at least 35 minutes. |
13 | $113 | $150 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$43,498
Total received (2018-2024)
Avg $6,214/year across 7 years
Top 1% in CA for dermatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
1,602
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$39,038 (89.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,346 (10.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$114 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,149
2023
$5,714
2022
$5,641
2021
$5,851
2020
$4,117
2019
$6,357
2018
$10,668
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,429
Amgen Inc.
$588
ABBVIE INC.
$382
Phathom Pharmaceuticals, Inc.
$345
GlaxoSmithKline, LLC.
$319
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$289
Boehringer Ingelheim Pharmaceuticals, Inc.
$267
Novo Nordisk Inc
$234
IRONWOOD PHARMACEUTICALS, INC
$228
E.R. Squibb & Sons, L.L.C.
$208
Bayer Healthcare Pharmaceuticals Inc.
$183
AIMMUNE THERAPEUTICS, INC.
$153
Radius Health, Inc.
$136
Mannkind Corporation
$88
Lilly USA, LLC
$87
Gilead Sciences, Inc.
$33
Kowa Pharmaceuticals America, Inc.
$31
Sumitomo Pharma America, Inc.
$30
ANI Pharmaceuticals, Inc.
$26
Otsuka America Pharmaceutical, Inc.
$22
Lundbeck LLC
$21
VIVUS LLC
$20
Azurity Pharmaceuticals, Inc.
$18
PFIZER INC.
$14
Top 3 companies account for 46.6% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$6,196
AstraZeneca Pharmaceuticals LP
$6,131
Amgen Inc.
$3,128
GlaxoSmithKline, LLC.
$2,414
Novo Nordisk Inc
$2,034
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,781
PFIZER INC.
$1,706
Amarin Pharma Inc.
$1,668
ABBVIE INC.
$1,553
Janssen Pharmaceuticals, Inc
$1,449
E.R. Squibb & Sons, L.L.C.
$1,429
Takeda Pharmaceuticals U.S.A., Inc.
$1,101
Lilly USA, LLC
$1,010
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$907
AbbVie Inc.
$807
Allergan Inc.
$683
Novartis Pharmaceuticals Corporation
$635
Avanir Pharmaceuticals, Inc.
$542
AbbVie, Inc.
$542
Radius Health, Inc.
$542
Esperion Therapeutics, Inc.
$521
Bayer Healthcare Pharmaceuticals Inc.
$469
Eisai Inc.
$449
Ironwood Pharmaceuticals, Inc
$414
Merck Sharp & Dohme Corporation
$356
Corium, LLC
$346
Phathom Pharmaceuticals, Inc.
$345
Bayer HealthCare Pharmaceuticals Inc.
$344
IRONWOOD PHARMACEUTICALS, INC
$319
Sunovion Pharmaceuticals Inc.
$313
Astellas Pharma US Inc
$269
Kowa Pharmaceuticals America, Inc.
$227
Sumitomo Pharma America, Inc.
$225
Almatica Pharma LLC
$218
Merck Sharp & Dohme LLC
$190
Horizon Therapeutics plc
$180
Ardelyx, Inc.
$171
SANOFI-AVENTIS U.S. LLC
$155
AIMMUNE THERAPEUTICS, INC.
$153
Hikma Pharmaceuticals USA
$145
Otsuka America Pharmaceutical, Inc.
$138
Biohaven Pharmaceuticals, Inc.
$125
RedHill Biopharma Inc.
$122
Allergan, Inc.
$98
Mannkind Corporation
$88
Scilex Pharmaceuticals Inc.
$80
GENZYME CORPORATION
$75
Lundbeck LLC
$64
EISAI INC.
$63
Eyevance Pharmaceuticals LLC
$62
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$61
VistaPharm, Inc.
$60
VIVUS LLC
$58
Genentech USA, Inc.
$55
Arbor Pharmaceuticals, Inc.
$43
ARBOR PHARMACEUTICALS, INC.
$36
ANI Pharmaceuticals, Inc.
$26
Paratek Pharmaceuticals, Inc.
$23
MannKind Corporation
$22
SCILEX PHARMACEUTICALS INC.
$22
Relypsa, Inc.
$22
Nestle HealthCare Nutrition Inc.
$21
Smith+Nephew, Inc.
$20
Sun Pharmaceutical Industries Inc.
$18
Azurity Pharmaceuticals, Inc.
$18
IBSA Pharma Inc.
$14
Top 3 companies account for 35.5% of all-time payments
Associated products mentioned in payments ›
ADLARITY · AFREZZA · AIRSUPRA · AMITIZA · ANORO · ANORO ELLIPTA · APTIOM · AREXVY · Adlarity · Aduhelm · Aimovig · Amitiza · BASAGLAR · BELSOMRA · BREO · BREZTRI · BREZTRI AEROSPHERE · BRILINTA · BYSTOLIC · CAMZYOS · CHANTIX · CIPRODEX · COLOGUARD · COLOGUARD DNA CAPTURE REAGENTS · CREON · Cequa · Creon · DUPIXENT · DUZALLO · Dayvigo · ELIQUIS · EMGALITY · ENTRESTO · EUCRISA · EVENITY · Edarbi · Edarbyclor · Epclusa · FARXIGA · FASENRA · GEMTESA · GRALISE · IBSRELA · INVOKANA · JANUVIA · JARDIANCE · KRYSTEXXA · Kerendia · LEQVIO · LINZESS · LIVALO · LOREEV XR · LYRICA · Licart · LifeVest · Linzess · Livalo · MOUNJARO · MYRBETRIQ · Mitigare · Motegrity · Myrbetriq · NAPRELAN · NEXLETOL · NEXLIZET · NUEDEXTA · NURTEC ODT · NUZYRA · Nuedexta · Otezla · Ozempic · PANCREAZE · PAXLOVID · PAZEO · PENNSAID · PNEUMOVAX 23 · PREMARIN · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Prolia · QULIPTA · REGRANEX · RELISTOR ORAL · REXULTI · RYBELSUS · Repatha · Rybelsus · SHINGRIX · SOLIQUA · SOLIQUA 100/33 · STEGLATRO · STIOLTO RESPIMAT · SYMBICORT · TOUJEO · TRADJENTA · TRELEGY ELLIPTA · TRINTELLIX · TRULANCE · TRULICITY · Talicia · Thyquidity · Tobradex ST · Tresiba · Trintellix · Tymlos · UBRELVY · VERQUVO · VESICARE · VIBERZI · VOQUEZNA · VOWST · VRAYLAR · Vascepa · Veltassa · Vemlidy · Victoza · XARELTO · XIFAXAN · Xofluza · ZENPEP · ZORYVE · ZTLido · ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH · Zerviate
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 1% for dermatology in CA.
Geographic Context
Dermatologists within 10 mi
565
Per 100K population
5.7
County median income
$87,760
Nearest hospital
L A DOWNTOWN MEDICAL CENTER
1.7 mi
1.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Pan is a clinical cardiology specialist, with above-average Medicare volume (top 12% in CA), with low-engagement industry engagement in the top 1% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Pan experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Pan performed 2,671 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pan receive payments from pharmaceutical companies?
Yes. Dr. Pan received a total of $43,498 from 66 companies across 1,602 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pan's costs compare to other dermatologists in Los Angeles?
Dr. Pan's average Medicare payment per service is $75. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Dermatology
Common procedures, typical costs, and what industry payments mean in dermatology.
Same specialty & city
Dermatologists in Los Angeles
Browse dermatologists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Dermatologists in CA
Dermatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Dermatologists in CA
Which CA dermatologists receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology